IL153004A0 - Modified morbillivirus v proteins - Google Patents
Modified morbillivirus v proteinsInfo
- Publication number
- IL153004A0 IL153004A0 IL15300401A IL15300401A IL153004A0 IL 153004 A0 IL153004 A0 IL 153004A0 IL 15300401 A IL15300401 A IL 15300401A IL 15300401 A IL15300401 A IL 15300401A IL 153004 A0 IL153004 A0 IL 153004A0
- Authority
- IL
- Israel
- Prior art keywords
- modified
- morbillivirus
- proteins
- morbilliviruses
- amino acids
- Prior art date
Links
- 241000712045 Morbillivirus Species 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 101900047836 Measles virus Non-structural protein V Proteins 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18461—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21365500P | 2000-06-23 | 2000-06-23 | |
PCT/US2001/019806 WO2002000694A2 (en) | 2000-06-23 | 2001-06-21 | Modified morbillivirus v proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153004A0 true IL153004A0 (en) | 2003-06-24 |
Family
ID=22795965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15300401A IL153004A0 (en) | 2000-06-23 | 2001-06-21 | Modified morbillivirus v proteins |
Country Status (17)
Country | Link |
---|---|
US (1) | US6664066B2 (es) |
EP (1) | EP1292615B1 (es) |
JP (1) | JP2004513616A (es) |
KR (1) | KR100885325B1 (es) |
CN (1) | CN1298738C (es) |
AT (1) | ATE343589T1 (es) |
AU (2) | AU2001267014B2 (es) |
BR (1) | BR0111827A (es) |
CA (1) | CA2409432C (es) |
CY (1) | CY1105842T1 (es) |
DE (1) | DE60124098T2 (es) |
DK (1) | DK1292615T3 (es) |
ES (1) | ES2273852T3 (es) |
IL (1) | IL153004A0 (es) |
MX (1) | MXPA02012256A (es) |
PT (1) | PT1292615E (es) |
WO (1) | WO2002000694A2 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1800697B1 (de) * | 2001-06-05 | 2010-04-14 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
WO2004113517A2 (en) | 2003-06-09 | 2004-12-29 | Wyeth | IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
US20090017517A1 (en) * | 2007-07-13 | 2009-01-15 | Medimmune, Llc | Preparation of Negative-Stranded RNA Viruses by Electroporation |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
EP3346005A1 (en) | 2008-01-31 | 2018-07-11 | CureVac AG | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
EP2804948B1 (en) * | 2012-01-20 | 2020-04-15 | The Government of The Hong Kong Special Administrative Region of The People's Republic of China | A novel paramyxovirus and uses thereof |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
SG11201510746WA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
US9552559B2 (en) | 2014-05-06 | 2017-01-24 | Elwha Llc | System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user |
US10458801B2 (en) | 2014-05-06 | 2019-10-29 | Uber Technologies, Inc. | Systems and methods for travel planning that calls for at least one transportation vehicle unit |
WO2015171772A1 (en) | 2014-05-06 | 2015-11-12 | Lord Robert W | System and methods for verifying that one or more end user transport directives do not conflict with one or more package delivery directives |
RU2017101210A (ru) * | 2014-07-18 | 2018-08-20 | Институт Насьональ Де Ла Санте Э Де Ла Решерш Медикаль (Инсерм) | Пептиды, включающие в себя домен, связывающий субъединицу вирусного фосфопротеина (р) с вирусным нуклеопротеином (n0), не содержащим рнк |
EP3183707A4 (en) | 2014-08-21 | 2018-02-28 | Uber Technologies Inc. | Arranging a transport service for a user based on the estimated time of arrival of the user |
US10685416B2 (en) | 2015-12-10 | 2020-06-16 | Uber Technologies, Inc. | Suggested pickup location for ride services |
US10731998B2 (en) | 2017-11-05 | 2020-08-04 | Uber Technologies, Inc. | Network computer system to arrange pooled transport services |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT702085E (pt) | 1994-07-18 | 2004-04-30 | Karl Klaus Conzelmann | Virus de arn de cadeia negativa nao segmentada infeccioso recombinante |
DE69510207T3 (de) | 1995-08-09 | 2007-02-15 | Schweiz. Serum- & Impfinstitut Bern | Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren |
JP2000517194A (ja) * | 1996-09-27 | 2000-12-26 | アメリカン・サイアナミド・カンパニー | モノネガビラレス(Mononegavirales)と称される目のウイルスにおける弱毒化の原因となる3’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異 |
CN1250725C (zh) | 1997-05-23 | 2006-04-12 | 美国政府健康及人类服务部 | 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法 |
BR9909076A (pt) * | 1998-03-26 | 2000-12-05 | American Cyanamid Co | Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b |
-
2001
- 2001-06-21 CN CNB018116426A patent/CN1298738C/zh not_active Expired - Fee Related
- 2001-06-21 AU AU2001267014A patent/AU2001267014B2/en not_active Ceased
- 2001-06-21 CA CA2409432A patent/CA2409432C/en not_active Expired - Fee Related
- 2001-06-21 BR BR0111827-7A patent/BR0111827A/pt not_active Application Discontinuation
- 2001-06-21 KR KR1020027017494A patent/KR100885325B1/ko not_active IP Right Cessation
- 2001-06-21 IL IL15300401A patent/IL153004A0/xx unknown
- 2001-06-21 PT PT01944623T patent/PT1292615E/pt unknown
- 2001-06-21 MX MXPA02012256A patent/MXPA02012256A/es active IP Right Grant
- 2001-06-21 AT AT01944623T patent/ATE343589T1/de not_active IP Right Cessation
- 2001-06-21 DK DK01944623T patent/DK1292615T3/da active
- 2001-06-21 EP EP01944623A patent/EP1292615B1/en not_active Expired - Lifetime
- 2001-06-21 JP JP2002505816A patent/JP2004513616A/ja active Pending
- 2001-06-21 ES ES01944623T patent/ES2273852T3/es not_active Expired - Lifetime
- 2001-06-21 US US10/311,582 patent/US6664066B2/en not_active Expired - Fee Related
- 2001-06-21 WO PCT/US2001/019806 patent/WO2002000694A2/en active IP Right Grant
- 2001-06-21 DE DE60124098T patent/DE60124098T2/de not_active Expired - Lifetime
- 2001-06-21 AU AU6701401A patent/AU6701401A/xx active Pending
-
2006
- 2006-12-11 CY CY20061101780T patent/CY1105842T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA02012256A (es) | 2003-04-25 |
ATE343589T1 (de) | 2006-11-15 |
EP1292615B1 (en) | 2006-10-25 |
DE60124098T2 (de) | 2007-04-05 |
CA2409432A1 (en) | 2002-01-03 |
BR0111827A (pt) | 2003-05-20 |
JP2004513616A (ja) | 2004-05-13 |
EP1292615A2 (en) | 2003-03-19 |
DK1292615T3 (da) | 2007-02-19 |
US20030206925A1 (en) | 2003-11-06 |
CY1105842T1 (el) | 2011-02-02 |
DE60124098D1 (de) | 2006-12-07 |
KR100885325B1 (ko) | 2009-02-25 |
KR20030032971A (ko) | 2003-04-26 |
AU2001267014B2 (en) | 2007-03-15 |
PT1292615E (pt) | 2007-01-31 |
ES2273852T3 (es) | 2007-05-16 |
CN1298738C (zh) | 2007-02-07 |
US6664066B2 (en) | 2003-12-16 |
CA2409432C (en) | 2010-08-03 |
WO2002000694A2 (en) | 2002-01-03 |
CN1437613A (zh) | 2003-08-20 |
AU6701401A (en) | 2002-01-08 |
WO2002000694A3 (en) | 2002-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL153004A0 (en) | Modified morbillivirus v proteins | |
DE3686304D1 (de) | Typenspezifische papillomavirus-dns-sequenzen und peptide. | |
ATE321867T1 (de) | Zusammensetzungen und methoden zur verwendung von dna polymerasen | |
EP1322307A4 (en) | METHODS OF TREATING CELL PROLIFERATION DISORDERS AND VIRAL INFECTIONS | |
ATE449850T1 (de) | Mutanten von flt3-l und ihre verwendungen | |
ES2134198T3 (es) | Mutaciones en la 5' a 3' exonucleasa de las adn polimerasas. | |
DE3586189D1 (de) | Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute. | |
MX343744B (es) | Antigenos de neisseria meningitidis y composiciones que los contienen. | |
CY1111006T1 (el) | Εκριμματαση ασθενειας alzheimer | |
BR9914374A (pt) | Sequências genÈmicas de neisseria e métodos para seu uso | |
ATE294855T1 (de) | Rna polymerase mutanten mit erhöhter thermostabilität | |
DK0750672T3 (da) | DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse | |
ATE255638T1 (de) | Nukleotidsequenzen und gegen cycloheximid resistente proteine | |
ATE307205T1 (de) | Gefrorenes lebensmittel | |
DE69736801D1 (de) | Gereinigte proteine, rekombinante dns-sequenzen und prozesse für die produktion von koffeinfreien getränken | |
AUPM772494A0 (en) | Improvements in production of proteins in host cells | |
WO2001006019A3 (en) | Nucleic acids for detecting parvovirus and methods of using same | |
FR2792651A1 (fr) | Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations | |
ATE380823T1 (de) | Rekombinante adhesin-proteine aus haemophilus influenzae | |
WO2003100075A3 (en) | Bsnd nucleic acids and proteins | |
Miller et al. | Endoglucanase A from Cellulomonas fimi in which the hinge sequence of human IgA1 is substituted for the linker connecting its two domains is hydrolyzed by IgA proteases from Neisseria gonorrhoeae | |
WO2002079459A3 (en) | Means for inhibiting proteolytical processing of parkin | |
Marusich et al. | Nucleotide and deduced amino acid sequences of bacteriophage T4 gene 22. | |
NO971359L (no) | Humant galaktokinase-gen | |
WO2003025004A3 (en) | Purified bacterial polypeptides involved in nucleic acid processing |